Baseline characteristics of patients with HCL and COVID-19
| Characteristics . | Sample (n = 40) . |
|---|---|
| Demographic characteristics | |
| Age, y | |
| Median (IQR | range) | 60 (52-67 | 43-89) |
| ≥70, n (%) | 7 (18) |
| Male sex, n (%) | 34 (85) |
| Comorbidities, n (%) | |
| Obesity | 2 (5) |
| Smoking history | 3 (8) |
| Chronic cardiovascular disease | 9 (23) |
| Diabetes | 2 (5) |
| Chronic pulmonary disease | 5 (13) |
| HCL characteristics | |
| Status at COVID-19 diagnosis, n (%) | |
| Onset: concurrent diagnosis | 7 (15) |
| Frontline therapy | 5 (13) |
| Remission | 11 (28) |
| Untreated stable disease | 15 (41) |
| Refractory disease | 1 (3) |
| Unknown | 1 (3) |
| Last treatment before COVID-19, n (%) | |
| No treatment | 19 (48) |
| Cladribine | 17 (43) |
| Rituximab | 2 (5) |
| Chlorambucil | 1 (3) |
| Corticosteroids | 1 (3) |
| COVID-19 characteristics | |
| Time between HCL diagnosis and COVID-19 (mo), median (IQR | range) | 14 (1-42 | 0-660) |
| Time between cladribine and COVID-19 (months), median (IQR | range) | 3 (2-32 | 0-223) |
| Vaccination | 5 (13) |
| SARS-CoV-2 variant | |
| Unknown | 32 (80) |
| Alpha | 2 (5) |
| Delta | 1 (3) |
| COVID-19 symptoms | |
| Pulmonary | 22 (55) |
| Extrapulmonary | 4 (10) |
| Pulmonary and extrapulmonary | 8 (20) |
| Severity* | |
| Asymptomatic | 3 (8) |
| Mild | 3 (8) |
| Severe | 19 (48) |
| Critical | 14 (35) |
| Neutrophiles at onset | |
| ≤500 | 6 (15) |
| 501-999 | 6 (15) |
| ≥1000 | 26 (65) |
| Lymphocytes at onset | |
| ≤200 | 8 (20) |
| 201-499 | 8 (20) |
| ≥500 | 21 (52) |
| Mortality | |
| Overall | 10 (26) |
| COVID-19 related | 9 (23) |
| Unknown reason | 1 (3) |
| Characteristics . | Sample (n = 40) . |
|---|---|
| Demographic characteristics | |
| Age, y | |
| Median (IQR | range) | 60 (52-67 | 43-89) |
| ≥70, n (%) | 7 (18) |
| Male sex, n (%) | 34 (85) |
| Comorbidities, n (%) | |
| Obesity | 2 (5) |
| Smoking history | 3 (8) |
| Chronic cardiovascular disease | 9 (23) |
| Diabetes | 2 (5) |
| Chronic pulmonary disease | 5 (13) |
| HCL characteristics | |
| Status at COVID-19 diagnosis, n (%) | |
| Onset: concurrent diagnosis | 7 (15) |
| Frontline therapy | 5 (13) |
| Remission | 11 (28) |
| Untreated stable disease | 15 (41) |
| Refractory disease | 1 (3) |
| Unknown | 1 (3) |
| Last treatment before COVID-19, n (%) | |
| No treatment | 19 (48) |
| Cladribine | 17 (43) |
| Rituximab | 2 (5) |
| Chlorambucil | 1 (3) |
| Corticosteroids | 1 (3) |
| COVID-19 characteristics | |
| Time between HCL diagnosis and COVID-19 (mo), median (IQR | range) | 14 (1-42 | 0-660) |
| Time between cladribine and COVID-19 (months), median (IQR | range) | 3 (2-32 | 0-223) |
| Vaccination | 5 (13) |
| SARS-CoV-2 variant | |
| Unknown | 32 (80) |
| Alpha | 2 (5) |
| Delta | 1 (3) |
| COVID-19 symptoms | |
| Pulmonary | 22 (55) |
| Extrapulmonary | 4 (10) |
| Pulmonary and extrapulmonary | 8 (20) |
| Severity* | |
| Asymptomatic | 3 (8) |
| Mild | 3 (8) |
| Severe | 19 (48) |
| Critical | 14 (35) |
| Neutrophiles at onset | |
| ≤500 | 6 (15) |
| 501-999 | 6 (15) |
| ≥1000 | 26 (65) |
| Lymphocytes at onset | |
| ≤200 | 8 (20) |
| 201-499 | 8 (20) |
| ≥500 | 21 (52) |
| Mortality | |
| Overall | 10 (26) |
| COVID-19 related | 9 (23) |
| Unknown reason | 1 (3) |
Asymptomatic is for patients without clinical signs or symptoms, mild for those with non-pneumonia and mild pneumonia, severe for those with dyspnea, respiratory frequency ≥30 breaths/min, SpO2 ≤ 93%, PaO2/FiO2 < 300, or lung infiltrates >50% on tomography, and critical for patients admitted in intensive care for respiratory failure, septic shock, or multiple organ dysfunction or failure.